An early analysis of data from late-stage clinical trials found that the vaccine was either 62% or 90% effective, depending on the manner in which the doses were given. On average, the vaccine was 70% effective, AstraZeneca said
A volunteer in Oxford, England, on Friday, Nov. 20, 2020, receives the coronavirus vaccine made by AstraZeneca and the University of Oxford. The drug maker AstraZeneca announced on Monday, Nov. 23, 2020, that an early analysis of some of its late-stage clinical trials showed that its coronavirus vaccine was 70.4 percent effective, on average, in preventing COVID-19. (Andrew Testa/The New York Times)
©2019 New York Times News Service